Cardiovascular Clinical Trials

Statistical methods in cardiovascular trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All cardiovascular trials

965 results

• ON TARGET DMIndependent statistical analysis of Comparison of Type 2 Diabetes Pharmacotherapy Regimens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073692).Phase NAResults postedn = 241,981NCT05073692
• On-OffIndependent statistical analysis of On Versus Off Pump Myocardial Revascularization Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290952).Phase 4Results postedn = 411NCT01290952
• Ondansetron and the QT Interval In Adult Emergency Department Patients: Complete Statistical AnalysisIndependent statistical analysis of Ondansetron and the QT Interval In Adult Emergency Department Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01759420).Phase NAResults postedn = 28NCT01759420
• One-Day Acceptance and Commitment Training Intervention in Primary Care Patients: Complete Statistical AnalysisIndependent statistical analysis of One-Day Acceptance and Commitment Training Intervention in Primary Care Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01879800).Phase NAResults postedn = 44NCT01879800
• ONTARGETAn independent statistical analysis of ONTARGET and its companion trial TRANSCEND: Cox hazard ratios for telmisartan, ramipril and their combination, the non-inferiority margin of 1.13, renal outcomes in diabetic nephropathy, and serious…Phase 4Results postedn = 31,546NCT00153101
• Onyx ONE ClearIndependent statistical analysis of A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear): primary endpoint results, effect estimate with…Phase NAResults postedn = 752NCT03647475
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 35NCT00950911
• Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 159NCT01190007
• Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05459688).Phase 2Results postedn = 175NCT05459688
• Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 216NCT03785405
• Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: Complete Statistical AnalysisIndependent statistical analysis of Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 23NCT00526071
• OPTIMASIndependent statistical analysis of OPTIMAS (NCT03759938), a randomized trial evaluating early versus standard initiation of direct oral anticoagulant treatment after acute ischaemic stroke in patients with atrial fibrillation.Phase NAn = 3,648NCT03759938
• OptiVol® Care Pathway: Complete Statistical AnalysisIndependent statistical analysis of OptiVol® Care Pathway: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00847288).Phase 4Results postedn = 1,682NCT00847288
• Oral Contraceptives in the Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Oral Contraceptives in the Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00205504).Phase 4Results postedn = 46NCT00205504
• Oral Nifedipine Versus Oral Labetalol: Complete Statistical AnalysisIndependent statistical analysis of Oral Nifedipine Versus Oral Labetalol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02168309).Phase NAResults postedn = 50NCT02168309
• ORBIT IIIndependent statistical analysis of Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 443NCT01092416
• ORBITA-2Independent statistical analysis of ORBITA-2, a randomized, quadruple-masked placebo-controlled trial of percutaneous coronary intervention for stable angina, including its design, primary endpoint, planned analysis, and statistical interpretation.Phase NAn = 439NCT03742050
• ORIGINComplete statistical analysis of the ORIGIN phase 3 trial, including its factorial design, cardiovascular and diabetes endpoints, Cox and log-rank methods, odds ratios, confidence intervals, and statistical interpretation.Phase 3Results postedn = 12,537NCT00069784
• ORIGINALComplete statistical analysis of the ORIGINAL phase 3 trial comparing tenecteplase with alteplase in Chinese patients with stroke, including trial design, non-inferiority methodology, efficacy, safety, and interpretation.Phase 3Results postedn = 1,489NCT04915729
• ORIONIndependent statistical analysis of EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 125NCT00896337
• ORION-4An independent statistical analysis of the randomized phase 3 ORION-4 trial evaluating inclisiran versus placebo for major adverse cardiovascular events in people with atherosclerotic cardiovascular disease.Phase 3n = 16,124NCT03705234
• Orthostatic Hypotension Treatment on Rehab Unit: Complete Statistical AnalysisIndependent statistical analysis of Orthostatic Hypotension Treatment on Rehab Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01030874).Phase NAResults postedn = 356NCT01030874
• Outlook Quality of Life Intervention: Complete Statistical AnalysisIndependent statistical analysis of Outlook Quality of Life Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00784095).Phase NAResults postedn = 36NCT00784095
• Outpatient and Home Advanced Rehabilitation Therapeutics Using Jintronix Virtual Reality Telerehabilitation System: Complete Statistical AnalysisIndependent statistical analysis of Outpatient and Home Advanced Rehabilitation Therapeutics Using Jintronix Virtual Reality Telerehabilitation System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 35NCT04333758
• OVATIONIndependent statistical analysis of Optimal VAsopressor titraTION Pilot Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01800877).Phase NAResults postedn = 120NCT01800877
• Oxytocin Effects on Cardiac Electrophysiology: Complete Statistical AnalysisIndependent statistical analysis of Oxytocin Effects on Cardiac Electrophysiology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01780337).Phase EARLY_1Results postedn = 12NCT01780337
• P2Independent statistical analysis of PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 902NCT02171065
• P3: Pacemaker Patient Profiling Study: Complete Statistical AnalysisIndependent statistical analysis of P3: Pacemaker Patient Profiling Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00294060).Phase NAResults postedn = 2,013NCT00294060
• PACE-RBBBIndependent statistical analysis of Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 16NCT01169493
• PACIFIC-AMIComplete statistical analysis of PACIFIC-AMI, the randomized phase 2 trial of asundexian versus placebo following acute myocardial infarction, including time-to-event endpoints, hazard ratios, confidence intervals, safety, and statistical interpretation.Phase 2Results postedn = 1,601NCT04304534
• PACIFIC-STROKEComplete statistical analysis of PACIFIC-STROKE, the randomized phase 2 trial of BAY 2433334 in patients following a recent non-cardioembolic ischemic stroke, including endpoint definitions, dose-response analysis, bleeding outcomes, hazard ratios, confidence intervals,…Phase 2Results postedn = 1,808NCT04304508
• PALISADEAn independent statistical analysis of PALISADE, a randomized phase 3 trial evaluating factor XI inhibition in adults with peripheral artery disease, including its time-to-event endpoints, trial design, planned statistical methods, and interpretation.Phase 3n = 7,050NCT07318610
• Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: Complete Statistical AnalysisIndependent statistical analysis of Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 100NCT01006629
• PALLASComplete statistical analysis of the PALLAS phase 3 trial of dronedarone versus placebo in patients with permanent atrial fibrillation, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, p-values, and statistical interpretation.Phase 3Results postedn = 3,236NCT01151137
• Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 9NCT03256045
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 83NCT02506959
• PANORAMA_3Independent statistical analysis of Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02654990).Phase 2Results postedn = 248NCT02654990
• PARADIGM-HFAn independent statistical analysis of PARADIGM-HF, the phase 3 randomized trial comparing LCZ696 with enalapril in patients with heart failure with reduced ejection fraction.Phase 3Results postedn = 8,442NCT01035255
• PARALLAXComplete statistical analysis of the PARALLAX phase 3 trial of sacubitril/valsartan versus individualized medical therapy in patients with heart failure with preserved ejection fraction, including endpoint definitions, mixed-effects and logistic regression methods,…Phase 3Results postedn = 2,572NCT03066804
• PASCALRegistryIndependent statistical analysis of Edwards PASCAL Transcatheter Valve Repair System Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04443218).Phase NAResults postedn = 220NCT04443218
• PATCHIndependent statistical analysis of Feasibility Study of the µCor Heart Failure and Arrhythmia Management System (PATCH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 51NCT04512703
• PATENT-1Independent statistical analysis of PATENT-1, a randomized phase 3 trial of oral riociguat in patients with pulmonary arterial hypertension, covering its 6-minute walking distance endpoint, ANCOVA, nonparametric and stratified analyses, secondary outcomes,…Phase 3Results postedn = 445NCT00810693
• PATHIndependent statistical analysis of Perindopril Amlodipine for the Treatment of Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01556997).Phase 3Results postedn = 837NCT01556997
• Patient Convenience Study (RE-SONANCE): Complete Statistical AnalysisIndependent statistical analysis of Patient Convenience Study (RE-SONANCE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02684981).Phase NAResults postedn = 9,472NCT02684981
• PATTErnIndependent statistical analysis of A Study of Physical Activity paTTerns and Major Health Events in Older People With Implantable Cardiac Devices: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 183NCT03544424
• PDT/PDLIndependent statistical analysis of Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 17NCT00556946
• PEACE IIIndependent statistical analysis of Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 23NCT02004158
• PEAR2Independent statistical analysis of Pharmacogenomic Evaluation of Antihypertensive Responses 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01203852).Phase 4Results postedn = 839NCT01203852
• Pecto-Intercostal Fascial Plane Block Study: Complete Statistical AnalysisIndependent statistical analysis of Pecto-Intercostal Fascial Plane Block Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04928339).Phase 4Results postedn = 100NCT04928339
• Peer Support Dyads in Churches: Complete Statistical AnalysisIndependent statistical analysis of Peer Support Dyads in Churches: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03463941).Phase NAResults postedn = 80NCT03463941

← All therapeutic areas